Option chain shows key data for Turnstone Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Turnstone Biologics.

Turnstone Biologics (NASDAQ:TSBX) Stock, Option Chain

Turnstone Biologics

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Alibaba.Fall20221.site_

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ASTS

BABA

CING

GAMB

LLAP

SIGA

TSBX

Crude Oil Gains Over 1%; Alibaba Posts Weak Revenue

Mysterious Disappearances At Walmart

Earnings

SPRC

Nasdaq Jumps Over 2%; Walmart Earnings Top Views

Amazing Lab Results

Biotech

Health Care

Movers

General

Turnstone Biologics stock drops after Phase 1 STARLING trial data reveals mixed results for TIDAL-01 in metastatic colorectal cancer, with a 25% response rate.

Turnstone Biologics Shifts Focus To &#39;High Unmet Medical Need&#39; Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study

Turnstone Biologics Corp

Press Releases

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Turnstone Biologics Announces Plans to Explore Strategic Alternatives

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CEL-SCI

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

GT Biopharma

HCW Biologics

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kairos Pharma

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Turnstone Biologics

Turnstone Biologics (TSBX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell